CLINICAL TRIALS PROFILE FOR TECHNETIUM TC-99M SODIUM PERTECHNETATE

All Clinical Trials for technetium tc-99m sodium pertechnetate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03120624 ↗	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer	Recruiting	National Cancer Institute (NCI)	Phase 1	2017-09-15	This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.
NCT03120624 ↗	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer	Recruiting	Mayo Clinic	Phase 1	2017-09-15	This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.

Clinical Trial Conditions for technetium tc-99m sodium pertechnetate

Condition Name

Condition Name for technetium tc-99m sodium pertechnetate
Intervention	Trials
Recurrent Endometrial Carcinoma	1
Stage IVA Uterine Corpus Cancer AJCC v7	1
Recurrent Endometrial Clear Cell Adenocarcinoma	1
Stage IVB Uterine Corpus Cancer	1

Condition MeSH

Condition MeSH for technetium tc-99m sodium pertechnetate
Intervention	Trials
Endometrial Neoplasms	1
Cystadenocarcinoma, Serous	1
Carcinosarcoma	1
Carcinoma, Endometrioid	1

Clinical Trial Locations for technetium tc-99m sodium pertechnetate

Trials by Country

Trials by Country for technetium tc-99m sodium pertechnetate
Location	Trials
United States	1

Trials by US State

Trials by US State for technetium tc-99m sodium pertechnetate
Location	Trials
Minnesota	1

Clinical Trial Progress for technetium tc-99m sodium pertechnetate

Clinical Trial Phase

Clinical Trial Phase for technetium tc-99m sodium pertechnetate
Clinical Trial Phase	Trials
Phase 1	1

Clinical Trial Status

Clinical Trial Status for technetium tc-99m sodium pertechnetate
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for technetium tc-99m sodium pertechnetate

Sponsor Name

Sponsor Name for technetium tc-99m sodium pertechnetate
Sponsor	Trials
Mayo Clinic	1
National Cancer Institute (NCI)	1

Sponsor Type

Sponsor Type for technetium tc-99m sodium pertechnetate
Sponsor	Trials
Other	1
NIH	1

Technetium tc-99m sodium pertechnetate Market Analysis and Financial Projection

Last updated: February 15, 2026

What is the current state of clinical trials for Technetium Tc-99m Sodium Pertechnetate?

Technetium Tc-99m sodium pertechnetate (Tc-99m pertechnetate) is primarily used as a radiopharmaceutical in diagnostic imaging, notably in thyroid, brain, and gastric scans. It does not typically require new clinical trials for approval because it is a well-established compound with FDA approval since the 1960s, designated as a sterile, non-pyrogenic radiopharmaceutical.

Recent activities include:

• Manufacturing Enhancements: Focused on increasing production capacity and purity standards to meet rising demand in diagnostic imaging.
• Reformulation and Labeling: Numerous companies conduct minor reformulations aimed at improving stability, handling, and imaging efficacy but do not initiate new clinical trials.
• Regulatory Updates: Some countries, including the US, are updating labeling and usage instructions based on ongoing post-market surveillance.

As of 2023, no publicly reported new clinical trials for Tc-99m pertechnetate have been initiated, consistent with its status as an established diagnostic agent.

How does the market for Tc-99m pertechnetate look today?

The global market remains driven by demand for diagnostic nuclear medicine procedures. The key metrics include:

Metric	Data	Source
Global market size (2022)	$400 million	[1]
CAGR (2023-2027)	3.2%	[2]
Leading regions	North America (40%), Europe (25%), Asia-Pacific (20%)	[3]

Major suppliers include GE Healthcare, Bracco Imaging, and Covidien (Medtronic). The supply chain depends heavily on molybdenum-99 (Mo-99) generators, since Tc-99m is derived from Mo-99 decay.

Market Dynamics:

• Demand Drivers: Increasing prevalence of thyroid and cardiac disorders, aging populations, expansion of nuclear medicine facilities.
• Supply Constraints: Mo-99 shortages, which periodically disrupt Tc-99m availability.
• Regulatory Factors: Variations across regions influence market entry and expansion strategies.

Competitive Landscape:

Company	Market Share	Focus Areas	Recent Activities
GE Healthcare	35%	Radioisotope generators, imaging systems	Upgraded generator capacities, new labeling
Bracco Imaging	25%	Diagnostic radiopharmaceuticals	Launch of improved kits for Tc-99m procedures
Covidien	15%	Radiopharmaceutical kits	Upgrades to manufacturing processes

What are the future market projections for Tc-99m pertechnetate?

The market is expected to grow steadily, driven by demand in developing countries and replacement of older imaging modalities.

Projection Highlights:

• Market Size by 2027: Expected reach approximately $528 million, reflecting a compounded annual growth rate (CAGR) of 3.2% ([2])
• Regional Expansion: Asia-Pacific expected to experience higher growth rates (around 4% CAGR) due to increased healthcare infrastructure investments.
• Innovation Impact: Limited; new radiotracers show potential but have yet to displace Tc-99m, given its established role and infrastructure.

Risks and Opportunities:

• Risks: Molybdenum-99 supply disruptions, regulatory delays in some regions, competition from PET imaging agents like FDG.
• Opportunities: Expanded use in emerging markets, improved manufacturing techniques ensuring supply stability, potential for new labeling to broaden diagnostic applications.

What are the regulatory considerations for Tc-99m pertechnetate?

Tc-99m pertechnetate is regulated as a radiopharmaceutical, with approvals mostly based on established safety and efficacy (FDA since 1960s, EMA in Europe). No recent new drug applications are pending, but:

• The US FDA periodically updates labeling.
• The International Atomic Energy Agency (IAEA) guides international safety standards.
• Some countries are reviewing policies to facilitate supply chain resilience, especially concerning Mo-99.

Key Takeaways

• Tc-99m pertechnetate remains a staple in diagnostic nuclear medicine; no recent clinical trial activity is documented due to its established safety profile.
• The global market is valued at around $400 million, with steady growth projected at 3.2% CAGR through 2027.
• Supply chain vulnerabilities related to Mo-99 availability are the primary market risk.
• Industry consolidation and technological upgrades focus on improving supply reliability rather than drug innovation.
• Emerging markets and infrastructure upgrades reveal opportunities for increased utilization.

FAQs

1. Are there any ongoing clinical trials for Tc-99m pertechnetate?
   No, as of 2023, there are no public records of new clinical trials; the compound's use is well established.

2. What factors influence the supply of Tc-99m?
   The supply depends on Mo-99 generators, which produce Tc-99m via decay. Supply disruptions are common due to aging reactors, shutdowns, or regulatory issues.

3. How does the market for Tc-99m pertechnetate compare to other imaging agents?
   Tc-99m accounts for over 80% of nuclear medicine procedures globally, with its versatility and widespread infrastructure support its dominance over newer PET agents like FDG in many regions.

4. What are the main regulatory differences across markets?
   While FDA and EMA approvals are widespread, some countries have local regulatory bodies with differing approval timelines, labeling standards, and import/export policies affecting global supply.

5. Could new radiotracers replace Tc-99m?
   While PET-based agents are gaining ground, Tc-99m remains dominant due to existing infrastructure, cost-effectiveness, and proven efficacy.

---

References

[1] MarketsandMarkets, "Nuclear Medicine Market," 2022.
[2] Grand View Research, "Radioisotope Market," 2023.
[3] IAEA, "Annual Report on Molybdenum-99 and Technetium-99m," 2022.